Brief: Vaccitech Doses First Patient In Prostate Cancer Phase 1/2 Clinical Trial
12/06/2023 12:40
June 12 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH DOSES FIRST PATIENT IN PCA001, A PROSTATE CANCER
PHASE
1/2 CLINICAL TRIAL OF VTP-850 IMMUNOTHERAPEUTIC CANDIDATE IN MEN
WITH RISING PSA AFTER DEFINITIVE LOCAL THERAPY
Source text for Eikon: ID:nGNXt3D58
Further company coverage: VACC.O
(reuters.briefs@thomsonreuters.com)
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing